Race Oncology Ltd has released a press release.
RC220 Meets Quality Specifications
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Impressive Bisantrene Phase 2 AML Clinical Results
- Trading Halt
- RC220 Peripheral Infusion Safety Confirmed
- RC220 Toxicology and Safety Pharmacology Studies Initiated
- Bisantrene cGMP API Manufacturing Completed at Laurus Labs
Later from Racura Oncology
- Dr Daniel Tillett appointed CEO of Race Oncology
- Updated Strategy and Investor Presentation
- Bonus Options Prospectus
- December 2023 Preclinical & Clinical Program Update
- Race Receives $4.0m R&D Tax Refund for Financial Year 2023
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology